Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2026)

Anaptysbio has reported Other Non-Current Liabilities for 10 years, with the latest figure at $263.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 20.17% year-over-year to $263.7 million; the trailing twelve-month figure through Mar 2026 stood at $263.7 million (down 20.17% YoY), and the FY2025 full-year result was $276.5 million, down 21.76% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $263.7 million, down from $276.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $362.0 million in Q2 2024, with the low at $35.0 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $294.5 million across 5 years, with a median of $310.2 million in 2024.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 789.35% — and 2025, when it decreased 21.76%.
• Anaptysbio's Other Non-Current Liabilities stood at $304.4 million in 2022, then climbed by 2.1% to $310.8 million in 2023, then grew by 13.71% to $353.4 million in 2024, then dropped by 21.76% to $276.5 million in 2025, then slipped by 4.62% to $263.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $263.7 million (Q1 2026), $276.5 million (Q4 2025), and $331.8 million (Q3 2025), per Business Quant data.